Precision Biopsy said today it raised $33.6 million in a new round of equity financing to support its ClariCore biopsy platform designed to provide prostate tissue classification during biopsy procedures. Woodford Investment Management led the round, according to Aurora, Colo.-based Precision Biopsy, with investments from its parent company Allied Minds. The ClariCore system is designed […]
Oncology
NovoCure prices $165m IPO
NovoCure priced its initial public offering today, saying it looks to raise $165 million by floating 7.5 million shares at $22 a piece. The company said it is also offering a 30-day underwriters option for an additional 1.1 million shares. NovoCure shares are slated to trade on the NASDAQ Global Select Market under the symbol “NVCR”. Last […]
NovoCure sets terms on $206m IPO
NovoCure today set the terms on its forthcoming initial public offering, saying it expects to float 7.5 million shares at $26 to $29 apiece, or $206.3 million at the midpoint of the range. NovoCure said it expects to net about $189 million from the offering, which includes an underwriters allotment for another nearly 1.9 million shares. Earlier this […]
Cardiovascular Systems reveals CEO Martin’s cancer diagnosis
Cardiovascular Systems (NSDQ:CSII) yesterday revealed that president & CEO David Martin will stay on the job while he undergoes treatment for Stage II stomach cancer. In a letter to employees, Martin wrote yesterday that his doctors believe his condition is curable. “My treatment plan is in place and I have begun chemotherapy, with surgery expected later […]
NovoCure files for $300m IPO
NovoCure registered for an initial public offering that could fetch as much as $300 million for its tumor-zapping Optune brain cancer treatment as it awaits a decision from the FDA on a new indication for the device. The federal safety watchdog granted pre-market approval for Optune in April 2011 for adult patients with glioblastoma whose cancer recurred after […]
After shelving $69m IPO, Mevion Medical lands $200m, launches China JV
Mevion Medical Systems, which last week shelved plans for a $69 million initial public offering, this week said it raised $200 million from a syndicate of Chinese and U.S. investors and launched a joint venture in the People’s Republic. President & CEO Joe Jachinowski told MassDevice.com today that Mevion, which makes the S250 proton therapy system, […]
Delcath prices $7m follow-on offering
Delcath (NSDQ:DCTH) said today it priced a follow-on offering of 9.3 million units of stock it plans to float at 75¢ per share, slated to bring in $7 million for the company. Each unit in the offering consists of a share of common stock, 0.75 of a Series A warrant to purchase common stock at 87¢, a […]
Navidea lands $60m for Lymphoseek
Edap, GE Healthcare join French-backed $45m liver cancer consortium
Delcath expands Phase II trial
Delcath Systems (NSDQ:DCTH) said it added 2 German research centers to a global Phase II trial of its Chemosat melphalan hepatic delivery system in treating primary liver cancer.